IRF5 and breast cancer: Further evidence confirming the role of myeloid based immune modulation is the observed upregulation of CXCL5 in both the BC and OS IRF5-low EV, a chemokine known to recruit MDSCs, and thus may be instrumental in understanding the mechanism of loss of IRF5 and MDSC recruitment (Fig. 5).